Effects of blocking TSLP on airway inflammation and the epithelial immune-response to exacerbation triggers in patients with COPD A randomized double-blind, placebo-controlled trial of Tezepelumab

Phase 1

• Conditions: Chronic obstructive pulmonary disease; Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

• Registration Number: CTIS2024-511730-12-00
• Lead Sponsor: Region Hovedstaden

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-04-25
• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Subjects with COPD on LABA+LAMA±ICS with = 1 exacerbation the past 12 months, Postbronchodilator FEV1 = 30% predicted (and = 1.0L) and < 80% predicted, Age 40 years or older

Exclusion Criteria

Exacerbation requiring oral corticosteroids or antibiotics (any dose for more than 3 days) 4 weeks prior to Visit 1 or during the run-in period, Any use of home oxygen therapy, Lung volume reduction surgery for COPD

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified